- Home
- PIM vs CHRS Comparison
PIM vs CHRS Comparison
Compare PIM & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PIM
- CHRS
- Stock Information
- Founded
- PIM 1988
- CHRS 2010
- Country
- PIM United States
- CHRS United States
- Employees
- PIM N/A
- CHRS N/A
- Industry
- PIM Finance Companies
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PIM Finance
- CHRS Health Care
- Exchange
- PIM Nasdaq
- CHRS Nasdaq
- Market Cap
- PIM 161.4M
- CHRS 84.2M
- IPO Year
- PIM N/A
- CHRS 2014
- Fundamental
- Price
- PIM $3.36
- CHRS $0.84
- Analyst Decision
- PIM
- CHRS Buy
- Analyst Count
- PIM 0
- CHRS 3
- Target Price
- PIM N/A
- CHRS $4.68
- AVG Volume (30 Days)
- PIM 57.5K
- CHRS 1.3M
- Earning Date
- PIM 01-01-0001
- CHRS 08-07-2025
- Dividend Yield
- PIM 8.28%
- CHRS N/A
- EPS Growth
- PIM N/A
- CHRS N/A
- EPS
- PIM 0.05
- CHRS N/A
- Revenue
- PIM N/A
- CHRS $272,251,000.00
- Revenue This Year
- PIM N/A
- CHRS N/A
- Revenue Next Year
- PIM N/A
- CHRS $106.56
- P/E Ratio
- PIM $63.80
- CHRS N/A
- Revenue Growth
- PIM N/A
- CHRS 19.87
- 52 Week Low
- PIM $2.90
- CHRS $0.66
- 52 Week High
- PIM $3.28
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- PIM 54.39
- CHRS 56.33
- Support Level
- PIM $3.34
- CHRS $0.73
- Resistance Level
- PIM $3.35
- CHRS $0.82
- Average True Range (ATR)
- PIM 0.03
- CHRS 0.04
- MACD
- PIM 0.00
- CHRS 0.01
- Stochastic Oscillator
- PIM 72.73
- CHRS 99.23
About PIM Putnam Master Intermediate Income Trust
Putnam Master Intermediate Income Trust is a closed-end fund. Its investment objective is to provide high current income and relative stability of net asset value. The fund pursues its goal by investing in U.S. high-grade, high-yield, and international fixed-income securities with limited maturities. The fund's portfolio includes the United States Government and agency mortgage obligations; mortgage-backed securities; corporate bonds and notes, and foreign government and agency bonds and notes.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.